Week in Review - 25 March 2016 Save
- phase 3, BRIDGE study shows romosozumab (anti-sclerostin MAb) significantly increases lumbar BMD in men with osteoporosis
- Statin use is associated with a 21% increased risk of skin cancer (NMSC) - data from >130K postmenopausal women (Womens Health Initiative)
- Metanalysis shows RA Xray progression is slower in recent yrs; cut in half after 1990 compared to before 1990; More progression seen with high levels of RF, CCP, CRP, ESR, and baseline erosions
- Chugai received orphan drug approval status for tocilizumab in #scleroderma (JAPAN Only); phase II trial in progress
- Increasing Polypharmacy and Drug Interactions in Seniors
- First Head-to-Head of 2 anti-TNF Trial Ends in a Draw: Certolizumab and Adalimumab yield same outcomes at 3 mos and 2 years.
- FDA Approves Taltz (ixekizumab) for Psoriasis - the UNCOVER 1, 2, 3 trials
- MMWR Update on Zika Virus: 116 US Cases Related to Travel
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.